January 17, 2024 – Saama, a leader of AI-based clinical trial solutions and services that accelerate drug development and commercialization, is pleased to announce the appointment of Avi Kulkarni, PhD, as Chief Customer Success and Growth Officer. Dr. Kulkarni brings to Saama more than 30 years of life sciences industry research and development innovation and leadership experience.
Dr. Kulkarni has a strong track record of leading teams in product development, clinical operations and commercialization, with companies such as Syneos Health, Cognizant, and IQVIA. Most recently, he was with Syneos Health where he was responsible for over $4 billion in annual clinical research organization (CRO) sales. Prior to that, he led Cognizant’s global life sciences strategic business unit, managing P&L execution for biopharma and medical device clients across research and development, IT, and digital functions. Additionally, Dr. Kulkarni serves on the Board of Directors at Diaceutics, a company specializing in personalized medicine.
In this role as Chief Customer Success and Growth Officer, Dr. Kulkarni is responsible for driving growth for both Saama’s AI-driven SaaS platform, as well as custom solutions and services. He will work alongside the broader executive management team to honor Saama’s commitment to fundamentally transform drug development, and accelerate the speed at which new treatments get to patients.
“We are thrilled to have Avi on board here at Saama,” said Vivek Sharma, Chief Executive Officer, Saama. “We are committed to helping our customers transform their clinical development processes with our AI-driven platform, and Avi’s leadership experience and expertise will help further accelerate this initiative.”
“I am delighted to join Saama as Chief Customer Success and Growth Officer,” said Dr. Kulkarni. “Clinical technologies both enable and deploy studies, and, when you introduce Saama’s AI-driven platform, it enables our customers to solve complex problems they face day in and day out, meeting unmet medical and technology-enablement needs, increasing process efficiency via innovation, and serving our industry-wide purpose of developing breakthrough medicines.”
Saama develops life science solutions that accelerate the delivery of therapies to patients. With innovative AI technologies, Saama drives breakthrough intelligence into clinical and commercial operations. The Saama platform powered the clinical trial that led to the world’s first COVID-19 vaccine. Headquartered in Campbell, CA, with employees around the globe, Saama is committed to helping customers save and improve lives. Discover more at saama.com.
Senior Director, Engagement Marketing
Catalytic Agency on behalf of Saama